53874-26-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-2,6-dimethylaniline is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Dye Industry:
In the dye industry, 3-Bromo-2,6-dimethylaniline is utilized as an intermediate in the production of dyes. Its chemical properties enable the creation of a range of colorants used in various applications, including textiles, plastics, and printing inks.
Used in Organic Chemistry Research and Development:
3-Bromo-2,6-dimethylaniline is employed as a building block in organic chemistry for research and development purposes. Its reactivity and structural features make it a valuable compound for creating new organic compounds and exploring novel chemical reactions.
Safety Note:
Due to its potential health and safety hazards, 3-Bromo-2,6-dimethylaniline should be handled and stored with care in appropriate laboratory conditions to ensure the safety of personnel and the integrity of the compound.

Upstream product

• 81-20-9 2,6-dimethylnitrobenzene 
• 39053-43-5 1-bromo-2,4-dimethyl-3-nitro-benzene 
• 7439-89-6 iron 

Downstream Products

• 26829-90-3 3,4-Dibromo-2,6-dimethylanilin 
• 129319-10-4 3-bromo-2,6-dimethylacetanilide 
• 63046-69-5 2-[(3-Bromo-2,6-dimethyl-phenyl)-(3-chloro-propionyl)-amino]-thiopropionic acid S-methyl ester 
• 145440-91-1 5-Methyl-isoxazole-3-carboxylic acid (3-bromo-2,6-dimethyl-phenyl)-amide 
• 15779-06-3 2-(3-Bromo-2,6-dimethyl-phenylamino)-benzoic acid 
• 53874-28-5 N-(3-Bromo-2,6-dimethyl-phenyl)-2-chloro-N-(2-ethoxy-ethyl)-acetamide 
• 1056963-14-4 2,6-dimethyl-3-(pyrrolidin-1-yl)aniline 
• 100445-96-3 3-amino-2,4-dimethyl-phenol 
• 26583-82-4 3-Fluor-2.4-dimethylbenzylalkohol 
• 26584-25-8 4-Fluor-2,3,5-trimethylbenzoesaeure 
• 26584-24-7 Methyl-4-fluor-2,3,5-trimethylbenzoat 
• 26583-81-3 3-fluoro-2,4-dimethylbenzoic acid 
• 26584-27-0 Methyl-3-fluor-2,4-dimethylbenzoat 
• 26583-83-5 3-Fluor-2.4-dimethylbenzylchlorid 

Relevant academic research and scientific papers

INHIBITING HUMAN INTEGRIN α4β7

Disclosed are small molecule antagonists of human α4β7 integrin, and methods of using them to treat a number of diseases and conditions.

BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS

The present disclosure provides a compound of general Formula (I) having c-abl kinase inhibitory activity or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method useful to treat or prevent neurodegenerative diseases using the compound.

From Naproxen Repurposing to Naproxen Analogues and Their Antiviral Activity against Influenza A Virus

The nucleoprotein (NP) of influenza A virus (IAV) required for IAV replication is a promising target for new antivirals. We previously identified by in silico screening naproxen being a dual inhibitor of NP and cyclooxygenase COX2, thus combining antivira

QUINAZOLINE COMPOUNDS

The present invention relates to quinazoline compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, R3, R4, R5, R6 and R7 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.

An electroluminescent compound and an electroluminescent device comprising the same

The present invention relates to an organic light emitting compound represented by chemical formula 1, and an organic electroluminescent device comprising the same. The organic light emitting compound according to the present invention increases PL quantu

THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS MODULATORS OF CCR9 RECEPTOR

Provided are compounds of Formula (I) or of Formula (II) that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or amelioratin diseases associated with modulation of CCR9 receptor activity.

Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists

The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.